Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
Molecular Partners announced the dosing of the first patients in a randomized Phase 2 TACTIC study evaluating MP0317 combined with chemoimmunotherapy for advanced cholangiocarcinoma. The trial aims to recruit 75 patients across nine active sites in a 2-to-1 randomization design to compare the experimental combination against standard-of-care alone.
Key figures
- Drug Name
- MP0317
- Phase Of Trial
- Phase 2
- Active sites
- 9
- Target patients
- 75
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.